CoChat

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes

Open access
Currie, Craig J., Poole, Chris D., Evans, Marc, Peters, John R., Morgan, Christopher Ll. · 2013 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

CONTEXT: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently undergone scrutiny. OBJECTIVE: The objective of the study was to characterize the risk of adverse events associated with glucose-lowering therapies in people with T2DM. DESIGN AND SETTING: This was a retrospective cohort study using data from the UK General Practice Research Database, 2000-2010. PATIENTS: Patients comprised 84 622 primary care patients with T2DM treated with one of five glucose-lowering regimens: metformin monotherapy, sulfonylurea monotherapy, insulin monotherapy, metformin plus sulfonylurea combination therapy, and insulin plus metformin combination therapy. There were 105 123 exposure periods. MAIN OUTCOME MEASURES: The risk of the first major adverse cardiac event, first cancer, or mortality was measured. Secondary outcomes included these individual constituents and microvascular complications. RESULTS: In the same model, and using metformin monotherapy as the referent, the adjusted hazard ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy (1.436, 95% confidence interval [CI] 1.354-1.523), insulin monotherapy (1.808, 95% CI 1.630-2.005), and insulin plus metformin (1.309, 95% CI 1.150-1.491). In glycosylated hemoglobin/morbidity subgroups, patients treated with insulin monotherapy had aHRs for the primary outcome ranging from 1.469 (95% CI 0.978-2.206) to 2.644 (95% CI 1.896-3.687). For all secondary outcomes, insulin monotherapy had increased aHRs: myocardial infarction (1.954, 95% CI 1.479-2.583), major adverse cardiac events (1.736, 95% CI 1.441-2.092), stroke (1.432, 95% CI 1.159-1.771), renal complications (3.504, 95% CI 2.718-4.518), neuropathy (2.146, 95% CI 1.832-2.514), eye complications (1.171, 95% CI 1.057-1.298), cancer (1.437, 95% CI 1.234-1.674), or all-cause mortality (2.197, 95% CI 1.983-2.434). When compared directly, aHRs were higher for insulin monotherapy vs all other regimens for the primary end point and all-cause mortality. CONCLUSIONS: In people with T2DM, exogenous insulin therapy was associated with an increased risk of diabetes-related complications, cancer, and all-cause mortality. Differences in baseline characteristics between treatment groups should be considered when interpreting these results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-3042

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Adjusted hazard ratios for insulin monotherapy vs metformin monotherapy. Baseline HbA1c was as follows: low, ≤8.4; medium, >8.4 and ≤10.2; high, >10.2. Morbidity was as follows: low, Charlson index = 1; high, Charlson index > 1.
Figure 1. Adjusted hazard ratios for insulin monotherapy vs metformin monotherapy. Baseline HbA1c was as follows: low, ≤8.4; medium, >8.4 and ≤10.2; high, >10.2. Morbidity was as follows: low, Charlson index = 1; high, Charlson index > 1.CC BY-NC · PubMed Central
Figure 2. Adjusted survival curves for each specific regimen vs insulin monotherapy for the primary end point. Blue line indicates insulin monotherapy. Red line indicates comparator. Model specification includes the following: age, gender, smoking history, prior primary care contacts, and Charlson index.
Figure 2. Adjusted survival curves for each specific regimen vs insulin monotherapy for the primary end point. Blue line indicates insulin monotherapy. Red line indicates comparator. Model specification includes the following: age, gender, smoking history, prior primary care contacts, and Charlson index.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 203

Metadata

Authors
Currie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L.
Affiliations
  • Cardiff University (GB)
  • University Hospital of Wales (GB)
Corresponding author
Currie, Craig J.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2013-02-01
Volume
98
Issue
2
Pages
668-677
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2157836715
Cited by
203
References
38
Citations by year
2026: 6 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 7 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 18 · 2016: 26 · 2015: 23 · 2014: 19 · 2013: 12
FWCI
21.02
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, insulin monotherapy, metformin, major adverse cardiac events, myocardial infarction, stroke, cancer risk, mortality, microvascular complications, renal complications, HbA1c, adverse drug reactions, primary care patients
MeSH terms
Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Prognosis, Retrospective Studies, Risk, Sulfonylurea Compounds, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.